Clinical-stage biotechnology company Insilico Medicine and pharmaceutical commercialization group China Medical System Holdings have announced a multi-project collaboration aimed at developing new therapies for central nervous system and autoimmune diseases using artificial intelligence-driven research.
Under the agreement, the companies will jointly advance at least two research and development programs that combine Insilico’s generative AI drug discovery platform with CMS’s clinical development and commercialization expertise. Insilico is expected to receive research funding support worth several tens of millions of Hong Kong dollars per program.
The partnership is structured to span the full pharmaceutical value chain — from target identification and molecular design to clinical trials and market launch. Insilico will deploy its Pharma.AI platform to discover and optimize small-molecule candidates, while CMS will guide clinical strategy, regulatory planning, trial execution and eventual commercialization.
Executives from both organizations said the collaboration is designed to shorten timelines and improve success rates in drug development, an area historically marked by high cost and failure rates. By sharing decision-making and integrating resources, the partners aim to accelerate the transition of laboratory discoveries into therapies available to patients.
CMS chairman Lam Kong described the collaboration as consistent with the company’s model of combining internal research with external innovation. He said the partnership would help bring first-in-class and best-in-class medicines to market more efficiently while improving affordability and accessibility.
Insilico co-CEO and chief scientific officer Feng Ren said the initiative represents a key step toward AI-enabled full-lifecycle drug research. He noted the companies plan to deepen cooperation in pipeline strategy, global partnerships and clinical planning as projects advance.
The announcement highlights growing industry interest in applying artificial intelligence to pharmaceutical development. Traditional early-stage drug discovery can take roughly four to five years before a viable preclinical candidate emerges. Insilico reports that between 2021 and 2024 it nominated 20 preclinical candidates in just 12 to 18 months per program, using significantly fewer synthesized molecules than conventional approaches.
If successful, the alliance could demonstrate how AI-assisted research combined with established clinical infrastructure can speed delivery of innovative therapies — particularly in complex disease areas such as neurological and immune disorders where unmet medical need remains high.